Business Monitor International


United Arab Emirates Pharmaceuticals & Healthcare Report

Published 25 March 2014

  • 122 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
United Arab Emirates Pharmaceuticals & Healthcare Report

BMI View: UAE's increasing investment from public and private sectors in its healthcare industry is set to bring improved standards of care and increased access to medicines, as well as making it a more appealing destination for medical tourists. Mandatory health insurance introduced in January 2014 will be beneficial to further market growth. However, drastic price cuts of drugs as a means of reducing government costs and the country's fragile economy, which remains highly sensitive to oil prices, pose risk to our positive healthcare outlook.

Headline Expenditure Projections:

  • Pharmaceuticals: AED7.02bn (US$1.91bn) in 2013 to AED7.44bn (US$2.03bn) in 2014; +5.9% in local currency and +6.0% in US dollar terms. Forecast in line with last quarter.

  • Healthcare: AED60.06bn (US$16.35bn) in 2013 to AED66.08bn (US$18.01bn) in 2014; +10.0% in local currency terms and +10.1% in US dollar terms. Forecast in line with last quarter.

Risk/Reward Rating

The UAE dropped one place in our Pharmaceutical Risk/Reward Rating (RRR). In Q2 2014 it ranked fourth out of a total of 30 markets in the Middle East and African region, with a score of 55.9.

Key Trends & Developments

March

Dubai has emerged as a medical tourism destination in the region, although much work is still required to fulfil its potential, according to the CEO of Dubai Healthcare City (DHCC), Marwan Abedin. The country needs to be promoted as a medical tourism destination and it needs to address the flow of patients outside the country. Medical tourism visas, which were announced in 2012, should soon come into effect.

Residents of the Central Region of Sharjah, the UAE, have complained that certain pharmacists are selling drugs at higher prices than others. It has been asserted that the absence of competent authorities has encouraged pharmacists to raise medicine prices. Patients suffering from chronic diseases are forced to buy drugs at higher prices due to the unavailability of drugs from government...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales Indicators 2010-2018
16
Healthcare Market Forecast
16
Table: Healthcare Expenditure Indicators 2010-2018
18
Table: Healthcare Governmental Indicators 2010-2018
18
Table: Healthcare Private Indicators 2010-2018
19
Prescription Drug Market Forecast
19
Table: UAE Healthcare Demand Split By Therapeutic Area
20
Table: Prescription Drug Sales Indicators 2010-2018
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, 2010-2018
24
Generic Drug Market Forecast
24
Table: Generic Drug Sales Indicators, 2010-2018
26
OTC Medicine Market Forecast
26
Table: OTC Medicine Sales Indicators, 2010-2018
27
Pharmaceutical Trade Forecast
28
Table: Exports And Imports Indicators, 2010-2018
29
Other Healthcare Data
30
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
32
Fiscal Position Remains Solid
34
Industry Risk Reward Ratings
36
Middle East And Africa Risk/Reward Ratings
36
United Arab Emirates Risk/Reward Ratings
44
Rewards
44
Risks
45
Market Overview
46
Industry Trends And Developments
48
Epidemiology
48
Table: UAE Healthcare Demand Split By Therapeutic Area
49
Healthcare Sector
53
Healthcare Sector Developments
55
Health Insurance
60
Research & Development
65
Regulatory Development
67
Regulatory Regime
67
Regulatory Developments
68
Pharmacovigilance
69
Pharmaceutical Advertising
69
Intellectual Property Issues
70
Pricing Regime
73
Pricing And Reimbursement Developments
74
Regional Harmonisation
76
Competitive Landscape
79
Pharmaceutical Sector
79
Table: Abu Dhabi's Top Five Best Selling Drugs In Value Terms By Therapeutic Area
79
Domestic Industry
80
Foreign Industry
82
Recent Company Developments
83
Pharmaceutical Distribution And Retail
84
Recent Developments
85
Company Profile
86
Julphar
86
Modern Pharmaceutical Company
90
Neopharma
92
Medpharma
96
GlaxoSmithKline
98
Pfizer
100
Novartis
102
Johnson & Johnson
104
Sanofi Aventis
106
Abbott Laboratories
108
Merck & Co
110
Demographic Forecast
112
Table: United Arab Emirates' Population By Age Group, 1990-2020 ('000)
113
Table: United Arab Emirates' Population By Age Group, 1990-2020 (% of total)
114
Table: United Arab Emirates' Key Population Ratios, 1990-2020
115
Table: United Arab Emirates' Rural And Urban Population, 1990-2020
115
Glossary
116
Methodology
118
Pharmaceutical Expenditure Forecast Model
118
Healthcare Expenditure Forecast Model
118
Notes On Methodology
119
Risk/Reward Ratings Methodology
120
Ratings Overview
121
Table: Pharmaceutical Risk/Reward Ratings Indicators
121
Indicator Weightings
122

The United Arab Emirates Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United Arab Emirates Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Emirati pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for United Arab Emirates to test other views - a key input for successful budgeting and strategic business planning in the Emirati pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Emirati pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in United Arab Emirates.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc